Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul E Verweij

Showing results (1-10 of 394) with videos related to

Pageof 40
Sort By:
The Lancet. Infectious Diseases|December 10, 2020
Fungal infections should be part of the core outcome set for COVID-19Paul E Verweij, Alexandre Alanio
The Journal of Antimicrobial Chemotherapy|April 18, 2009
The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Moulds: diagnosis and treatmentPaul E Verweij, Johan Maertens
The Pediatric Infectious Disease Journal|February 5, 2013
Update on antifungal resistance in children: epidemiology and recommendationsPaul E Verweij, Adilia Warris
The Journal of Infectious Diseases|September 16, 2017
Animal Models for Studying Triazole Resistance in Aspergillus fumigatusRussell E Lewis, Paul E Verweij
Current Opinion in Infectious Diseases|July 14, 2020
Aspergillus fumigatus and pan-azole resistance: who should be concerned?Nathan P Wiederhold, Paul E Verweij
Cornea|December 28, 2002
Combination therapy for keratitis by the fungus ScedosporiumEric Nulens, Cathrien Eggink, Paul E Verweij
Lancet (London, England)|May 16, 2003
Culture and infection controlAndreas Voss, Tanja Schülin, Paul E Verweij
Current Opinion in Infectious Diseases|October 16, 2013
Azole resistance in Aspergillus fumigatus: a growing public health concernEdith Vermeulen, Katrien Lagrou, Paul E Verweij
Expert Review of Anti-Infective Therapy|December 10, 2014
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseasesSeyedmojtaba Seyedmousavi, Paul E Verweij, Johan W Mouton
The New England Journal of Medicine|December 27, 2002
Multidrug resistance in Aspergillus fumigatusAdilia Warris, Corry M Weemaes, Paul E Verweij
Pageof 40

Showing results (1-10 of 394) with videos related to

Sort By:
Pageof 40
The Lancet. Infectious Diseases|December 10, 2020
Fungal infections should be part of the core outcome set for COVID-19Paul E Verweij, Alexandre Alanio
The Journal of Antimicrobial Chemotherapy|April 18, 2009
The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Moulds: diagnosis and treatmentPaul E Verweij, Johan Maertens
The Pediatric Infectious Disease Journal|February 5, 2013
Update on antifungal resistance in children: epidemiology and recommendationsPaul E Verweij, Adilia Warris
The Journal of Infectious Diseases|September 16, 2017
Animal Models for Studying Triazole Resistance in Aspergillus fumigatusRussell E Lewis, Paul E Verweij
Current Opinion in Infectious Diseases|July 14, 2020
Aspergillus fumigatus and pan-azole resistance: who should be concerned?Nathan P Wiederhold, Paul E Verweij
Cornea|December 28, 2002
Combination therapy for keratitis by the fungus ScedosporiumEric Nulens, Cathrien Eggink, Paul E Verweij
Lancet (London, England)|May 16, 2003
Culture and infection controlAndreas Voss, Tanja Schülin, Paul E Verweij
Current Opinion in Infectious Diseases|October 16, 2013
Azole resistance in Aspergillus fumigatus: a growing public health concernEdith Vermeulen, Katrien Lagrou, Paul E Verweij
Expert Review of Anti-Infective Therapy|December 10, 2014
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseasesSeyedmojtaba Seyedmousavi, Paul E Verweij, Johan W Mouton
The New England Journal of Medicine|December 27, 2002
Multidrug resistance in Aspergillus fumigatusAdilia Warris, Corry M Weemaes, Paul E Verweij
Pageof 40